RISPERIDONE IN ANOREXIA NERVOSA

To the Editor:
The value of medication in the treatment of anorexia nervosa (AN) is uncertain, and to date, no placebo-amrrolled ). AM. ACAD. CHILO AOOLESC. l 'SYCHtATRY, 39:6, AUGUST 2000 studies have demonstrated its utility for weight gain Oimerson et al., 1996) . The delusional fear of w~ight gain raises the question of wh.ether atypical antipsychotics could be helpful. There is only one case report of risperidone being used in a high-functioning autistic female with AN, but the medication was used to target her paranoia and aggressiveness (Fisman et al., 1996) . I describe 2 cases of female adolescents with severe AN who rapidly improved after the addition of risperidone to a selective serotonin rcuptake inhibitor.
J.P. is a 19-year-old woman with a 5-ycar history of AN who denied bingeing, purging, and diuretic or laxative use. At 5 feet 2.5 inches (158 em), her weight was 80 lb (36.4 kg) and body mass indo (BMI) was 14.6 kglm 2 ; she had secondary amenorrhea and moderate osteopenia. She denied hallucinations or delusions unrelated to her eating disorder, Multimodal treatment including sequential full trials of fluvoxamine, paroxetine, fluoxetine, and semaline did not help her major depression or weight. ln February 1998, at less than 70% of ideal body weight (IBW), she was hospitalized for bradycardia. During a 3-month psychiatric hospitalization, she gained 20 lb but was unable to maintain her weight after discharge; she was hospitaliud again 4 months lau:r. Venlafaxine 150 mg b.i.d. lessened her depression, but she continued to lose weight as an outpatient. In December 1998, I added risperidone 1.5 mglday for her delusional thinking about weight and to avoid a third hospitalization. Within 1 week, J.P.'s anxiety and obsessions about food diminished. During the nc:xr month, she: gained 16 lb to reach 105 lb, 91 o/o of IBW. Although she was dimessed about the rapidity of her weight gain, her depression remitted. Her meal plan was decreased from 3,500 to 2,500 kcal/day, and in Aprill999, at 109 lb, 97% ofiBW. her menses returned. Over the next 10 months, her focus on body image and weight declined and she remained at IBW with regular memes even after risperidone was tapered and discontinued.
M.R. is a 12-year-old girl with a 2-year history of a restrictive eating disorder with secondary amenorrhea, who denied bingeing. purging, and l:oo.tive or diuretic use. Sh.e denied hallucinations and delusions unrelated to body image. At 5 feet 1.5 inche..~ (154 em), 83lb (37.7 kg), BMI of 15.9, she was 79% of IBW and required medical hospitalization for bradycardia. Sertraline 100 mg minimally helped her anxiety, obsessive thoughts about food, and minor depression. She was unable to gain weight as an outpatient, so to avoid another hospitalization I added risperidone 0.5 mglday in January 1999. Within 1 week, M.R could follow her meal plan, was more cheerful and energetic:, and expressed new insight about her anore~eia. M.R. incrascd her rispcridonc dosage to 0.5 mg t.i.d. as it lowered her anxiety bc:fore meals. She gained 8 lb the firS[ month and 4 lb the second month, reaching 95 lb, 91% of IBW. In May 1999, after her rispcridone dosage was decreased to 0. 5 mg b.i.d., her insight declined and ob5CSSive thinking about "WCight returned, but both quickly improved when the risperidone dose was increased to 1.5 mglday. In September 1999, at 103lb, her menses returned. She hu since maintained her "WCight and menses for 6 months and tqJOrtS that she rudy thinks about food or 'NCight.
Both adolescents ccedited risperidone for their avoidance of another hospitalization and rapid improvement in thinking about food and body image. Both families bdic:vcd !hat their child's irritability and abnormal mealtime behavior improved greatly with the addition of this medication. Atypical antipsychotia may be beneficial for patients with AN, even those without dear psychosis, bcause of the delwional nature of body image distortions and the large weight gain associated with these medications. In addition to inc~ing appetites, risperidone may slow metabolism as J.P. gained weight despite decreasing her superviled daily caloric intake. Although one would expect that patients with AN would dislike a medication that leads to weight gain, both of these patients wished to continue to take the medication, and M.R. even requested that her dose be raised. They both expressed kding more "in control" of their thinking while mlcing the medication.
The only side d&ct experienced by these 2 adolescentS was mild initial sedation. They did not dcvdop dyskinetic movements, and phosphate and liver function test results remained normal. The QTc interval on J.P.'s electrocardiogram (ECG) increased from 400 to 421 milliseconds; thus monitoring ECGs may be indicated in this population. Although risperidonc is a medication with potential serious risb, the high morbidity and monality rates associated with AN may warrant the cautious use of rispcridone for some patients. a1., 1988; Kinzie and Leung, 1989) . Antidepressants--selective serotonin reuprakc inhibirors (SSRis) in particular-have been shown to exert some benefit in adults, but a recent literature review (Donnelly ct al., 1999) found no reports of SSRJ use in pediatric PTSD. Currclltly nc:fazodone is being examined as a possible treatment in adults and has been shown to have some beneficial effects in open trials. We wish to report the potential U3eful-ncss of ncfazodone in adolescents with PTSD.
Many adolescents with PTSD arc brought to the attention of mental health providers because of difficulties with behavior. ln fact, many of the patients assessed in our clinics or admitted to our residential treatment programs present not for problenu with avoidance, excessive worry, or reexperiencing phenomena, but for disruptive behaviors at home and in the community. We have found that nefazodonc may be particularly useful in addressing the symptoms of hypcrarousal which bring adolescents to clinical attention. These include improvements not only in anger and aggression, but in restlessness, insomnia, and even concentration. In the context of residential treatment we have observed an improvement in avoidance, anhedonia, and detachment. Our patients often report an improvement in both sleep duration and quality. Improvement in sleep and the symptoms of hyperarowal arc consistent with those changes observed in adult patients with PTSD (Hertzberg ct al., 1998).
A 1997 case study (Wilens et al.) discussed the efficacy of nefazodonc in children and adolescents with mood disorders.
The authors concluded that nefazodone was 'NCll tolerated and showed some benefit. In our adolescent population we have also found rhar it is well tolerated in doses of up to 600 mgl day. with an average effective dose of around 200 mg twice per day. While one &male patient has reported visual trails at a dosage of 600 mglday (which resolved with a decrease in dos· age), the most common complaints have been of morning somnolence, nausea, and vomiting. These side effects seem to occur more commonly at higher doses. The nausea and vomiting seem to be dose-related and tend to improve with a dccrea.sc in dosage. We have, however, had 3 patients (ovc:r the course of the past 3 years) who required disconEinuation of the med· ication because of nawca. Somnolence has not been as much of a problem with patients who were significantly activated before its initiation.
Psychotherapy has long been the primary treatment for PTSD, both in adolescents and in adults. It stands to reason that if the problematic symptoms of hyperarousal and avoidance can be attenuated, then psychotherapy may in turn be
